Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Carlos Alvarez Fernandez"'
Autor:
Carlos Álvarez Fernández
Publikováno v:
Hispania Sacra, Vol 76, Iss 153 (2024)
Este artículo se propone caracterizar las políticas franquistas dirigidas sobre el cuerpo y la sexualidad de las mujeres, poniendo el acento en el terreno de las agresiones sexuales. El triunfo del bando sublevado supuso la implantación del discur
Externí odkaz:
https://doaj.org/article/b9c0d68a8bfe4ac4ae82c6c488fca89f
Autor:
Maria Jose Juan FITA, Urbano Anido Herranz, Maria Jose Mendez Vidal, Regina Gironés, Begoña Mellado-Gonzalez, José Manuel Sepulveda Sánchez, Carlos Alvarez-Fernandez, Miguel Ángel Climent, Lucia Heras
Publikováno v:
Journal of Clinical Oncology. 41:168-168
168 Background: Prostate cancer is the second most common cancer in men. A number of important systemic therapies have been developed to treat mCRPC and now comprise the current therapeutic landscape. Docetaxel became the first systemic therapy to im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e53700cfd08120d2599b6e4483fb21f
https://doi.org/10.1200/jco.2023.41.6_suppl.168
https://doi.org/10.1200/jco.2023.41.6_suppl.168
Autor:
Thomas Powles, Srikala S. Sridhar, Yohann Loriot, Joaquim Bellmunt, Xinmeng Jasmine Mu, Keith A. Ching, Jie Pu, Cora N. Sternberg, Daniel P. Petrylak, Rosa Tambaro, Louis M. Dourthe, Carlos Alvarez-Fernandez, Maureen Aarts, Alessandra di Pietro, Petros Grivas, Craig B. Davis
Publikováno v:
Nature Medicine, 27(12), 2200-2211. Nature Publishing Group
In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432), avelumab/best supportive care (BSC) significantly prolonged overall survival relative to BSC alone as maintenance therapy after f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b302fa5cd683152280f70c1f410d347
http://hdl.handle.net/10230/54073
http://hdl.handle.net/10230/54073
Autor:
Sergio Vazquez-Estevez, Ovidio Fernandez-Calvo, Teresa Bonfill-Abella, Silvia Sequero, Francisca Martínez-Madueño, Nuria Romero-Laorden, Montserrat Domenech-Santasusana, Elena Sevillano, José García Sánchez, Carlos Alvarez-Fernandez, Cristina Núñez-González
Publikováno v:
Journal of Clinical Oncology. 40:4588-4588
4588 Background: Combined-modality treatments are bladder-preserving alternatives for patients (pts) who are not candidates for radical cystectomy by medical reasons, refusal, or patient´s choice. Immune therapies seem to potentiate tumor-specific i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbe6df2a27ac4d67eaee0c4f47d5708b
https://doi.org/10.1200/jco.2022.40.16_suppl.4588
https://doi.org/10.1200/jco.2022.40.16_suppl.4588
Autor:
Juan Francisco Rodriguez-Moreno, Sergio Ruiz-Llorente, Guillermo De Velasco, Carlos Alvarez-Fernandez, Ricardo Collado Martín, Ricardo Fernandez, Sergio Vazquez-Estevez, Juan Antonio Virizuela, Pablo Gajate, Albert Font, Nuria Lainez, Arantzazu Barquin, Luis Beltran, Cristina Rodriguez-Antona, Pedro Berraondo, Jesús García-Donas
Publikováno v:
Journal of Clinical Oncology. 40:546-546
546 Background: Immune checkpoint inhibitors have been incorporated to early-stage bladder carcinoma treatment recently. Durvalumab is a PD-L1 blocking antibody active in advance urothelial tumors and under evaluation in other settings of the disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b20f248cb6814e5981ec9f9472e25bf1
https://doi.org/10.1200/jco.2022.40.6_suppl.546
https://doi.org/10.1200/jco.2022.40.6_suppl.546
Autor:
Miguel Angel A. Climent Duran, Jose Luis Perez-Gracia, Jose Angel Arranz Arija, Carlos Alvarez-Fernandez, Jenifer Gomez Mediavilla, Angel Rodriguez, Sergio Vazquez-Estevez, Jose Miguel Jurado, Carmen Santander, Teresa Bonfill, Carmen Molins Palau, Sara Perez Ramirez, Paola Pimentel Cáceres, Pablo Arnáiz, Zita Garate, Atenea Soto, Javier Puente
Publikováno v:
Journal of Clinical Oncology. 40:484-484
484 Background: Atezolizumab is a monoclonal antibody with proven efficacy in clinical trials for advanced or metastatic urothelial carcinoma (UC) after progression to platinum-based chemotherapy. Following EMA marketing authorization and before priz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b92b6d8cc15799ca2eeafa06306e7d84
https://doi.org/10.1200/jco.2022.40.6_suppl.484
https://doi.org/10.1200/jco.2022.40.6_suppl.484
Publikováno v:
The American journal of hospicepalliative care. 36(12)
Palmitoylethanolamide (PEA) is a nutraceutical endocannabinoid that was retrospectively discovered in egg yolks. Feeding poor children with known streptococcal infections prevented rheumatic fever. Subsequently, it was found to alter the course of in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc25a2f5bfd477723d8052ebeec4b822
https://pubmed.ncbi.nlm.nih.gov/31113223
https://pubmed.ncbi.nlm.nih.gov/31113223
Autor:
Alejandro González, Diego A. Gómez, Emilio Esteban, J. del Río Fernández, Noemi Villanueva, Carlos Alvarez-Fernandez, Debora Corina Contreras Toledo, P. Jiménez-Fonseca, Sena Valcárcel González, Clara Iglesias Gomez, Alfonso Revuelta, M. Izquierdo, Maria Pilar Solis-Hernandez, Sara Fernandez Arrojo, V. V. Durantez, Luka Mihic Góngora
Publikováno v:
Journal of Clinical Oncology. 39:e24098-e24098
e24098 Background: Patient reported outcomes measures (PROMs) represent a tool to objectively assess the health of cancer patients. PROMs may complement oncological evaluations by adding patients’ perspectives on their care priorities. Aim: to addr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5c7394be5518a8fb71920a6d6d468f1
https://doi.org/10.1200/jco.2021.39.15_suppl.e24098
https://doi.org/10.1200/jco.2021.39.15_suppl.e24098
Publikováno v:
Medicina Clínica. 146:2-6
In the last 10 years, there has been a major change in the treatment of lung cancer (LC). The discovery of activating mutations in the epidermal growth factor receptor (EGFR) in some histological subtypes of LC and its sensitivity to tyrosine kinase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c080531adb8f4c33c9495070d4a78e6
https://doi.org/10.1016/s0025-7753(16)30256-1
https://doi.org/10.1016/s0025-7753(16)30256-1
Autor:
Rosa Collado, E. Sevillano Fernandez, Carlos Alvarez-Fernandez, G. De Velasco, P. Gajate Borau, Saray Galvan Ruiz, A. Font, Juan Francisco Rodriguez-Moreno, Nuria Lainez, Pedro Berraondo, Luis Beltran, R. Fernandez-Rodriguez, Cristina Rodríguez-Antona, J.A. Virizuela Echaburu, Jesús García-Donas, S. Vazquez Estevez
Publikováno v:
Annals of Oncology. 31:S589
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fd3d22e662c639b880d4afbc8f670fe
https://doi.org/10.1016/j.annonc.2020.08.833
https://doi.org/10.1016/j.annonc.2020.08.833